REGINfo: VIFOR PHARMA - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$VIFOR PHARMA: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2020.03.31 | 05:00 | Annual General Meeting / AGM

puce Update on 92nd Vifor Pharma Ltd. Annual General Meeting - HTML (w)

2020.03.31 | 05:00 | Annual General Meeting / AGM

puce Communiqué concernant la 92e assemblée générale annuelle de Vifor Pharma SA - HTML (w)

2020.03.12 | 06:00 | Permanent Information Releases / General Company News

puce Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance - HTML (w)

2020.03.12 | 06:00 | Permanent Information Releases / General Company News

puce En 2019, le groupe Vifor Pharma a enregistré une forte croissance, supérieure aux prévisions - HTML (w)

2020.02.20 | 06:00 | Permanent Information Releases / General Company News

puce Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio - HTML (w)

2019.11.26 | 07:00 | Permanent Information Releases / General Company News

puce Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously - HTML (w)

2019.11.26 | 06:00 | Permanent Information Releases / General Company News

puce VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA Associated Vasculitis - HTML (w)

2019.08.08 | Periodic information / Half-Year Financial Report

puce VIFOR PHARMA : HALF-YEAR REPORT 2019 - PDF (3Mb)

2019.05.21 | 05:00 | Permanent Information Releases / General Company News

puce First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy - HTML (w)

2019.05.10 | 19:30 | Permanent Information Releases / General Company News

puce Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint - HTML (w)

2019.05.08 | 15:48 | Annual General Meeting / AGM

puce 91st Vifor Pharma Group Annual Shareholder Meeting - HTML (w)

2019.05.08 | 15:48 | Annual General Meeting / AGM

puce 91e Assemblée Générale du Groupe Vifor Pharma - HTML (w)

2019.04.09 | 05:00 | Permanent Information Releases / General Company News

puce Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement - HTML (w)

2019.03.14 | 06:00 | Permanent Information Releases / Sales and Revenues

puce LE GROUPE VIFOR PHARMA PUBLIE DE SOLIDES RÉSULTATS 2018 SUPÉRIEURS AUX PRÉVISIONS - HTML (w)

2019.03.14 | 06:00 | Permanent Information Releases / Sales and Revenues

puce Vifor Pharma Group Reports Strong 2018 Results, Exceeding Raised Guidance - HTML (w)

Pages : 1 - 2 / Doc nb : 24